References
- World Health Organization. Antituberculosis drug resistance in the world. WHO/HTM/TB/2004;343. Accessed from the website: http://www.who.int/tb/publications/who_htm_tb_2004_ 343/en.
- World Health Organization. Treatment of tuberculosis: Guidelines for National Programs. 2nd ed. Geneva: WHO; 1997.
- Kim S, Park YJ, Kim WI. Molecular analysis of Isoniazid resistance in mycobacterium tuberculosis isolates recovered from South Korea. Diagn Microbiol Infect Dis 2003;47(3):497–502.
- Shishoo CJ, Shah SA, Rathod IS, Savale SS, Kotecha JS, Shah PB. Stability of Rifampicin in dissolution media in the presence of isoniazid. Int J Pharm 1999;190:109–123.
- Singh S, Mariappan TT, Sankar R, Sarda N. A critical review of the probable reasons for the poor variable bioavailability of Rifampicin from antitubercular fixed dose combination products, and the likely solutions to the problem. Int J Pharm 2001;228:5–17.
- Singh S, Mariappan TT, Sarda N, Sanjeev K, Chakraborty AK. The reason for an increase in decomposition of Rifampicin in the presence of Isoniazid under acidic conditions. Pharm Pharmacol Commun 2000;6:405–410.
- Long MW, Snider DR, Farer LS. US public health service comparative trial of three RIF-INH regimens in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979;119:879–894.
- Singh S, Mohan BH. A pilot stability study on four drug fixed dose combination anti tubercular products. Int J Tuberc Lung Dis 2003;7(3):298–303.
- Prabhakaran D, Singh P, Jaganathan KS, Vyas SP. Osmotically regulated asymmetric capsular systems for simultaneous sustained delivery of antitubercular drugs. J Control Release 2004;95:239–248.
- Hiremath PS, Saha RN. Oral matrix tablet formulations for concomitant controlled release of anti-tubercular drugs: Design and in vitro evaluations. Int J Pharm 2008;36(2):118–125.
- Singh A, Jain R. Pharmaceutical compositions of anti-tubercular drugs and process for their preparation. US Patent 7195769, 2007.
- United States Pharmacopeia and National Formulary (USP 30-NF 25). Vol. 2. Rockville, MD: United States Pharmacopeia Convention; 2007:1553–1554.
- Sriamornsak P, Thirawong N, Korkerd K. Swelling, erosion and release behaviour of alginate-based matrix tablets. Eur J Pharm Biopharm 2007;66:435–450.
- Helsinki declarations world medical association: Declaration of Helsinki adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964. Amended by the 29th World Medical Assembly, Tokyo, Japan, October 1975; 35th World Medical Assembly, Venice, Italy, October 1983; and the 41st World Medical Assembly, Hong Kong, September 1989.